Clinical Trial Update: Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of homoharringtonine plus low-dose cytarabine in newly diagnosed chronic myeloid leukemia in chronic phase; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Bcr-abl1-positive Chronic Phase

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Homoharringtonine (homoharringtonine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED